Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) and Johns Hopkins University have successfully submitted our proposal for a NIH Grant that will utilize CTT's patented technology as a smoking cessation ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

Bangalore: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval ...

India vs Australia highlights, 4th Test Day 2: Australia’s fierce pace attack dismantled India’s top order on Friday, taking control of the fourth Test after setting a formidable first-innings ...

The approval encompasses generic versions of Victoza for Type-2 Diabetes treatment and Saxenda for weight management. Management expects strong growth in Biocon’s formulations business during the ...

While all state Medicaid programs include GLP-1s prescribed for Type 2 diabetes, only 36 states cover at least one of the FDA-approved GLP-1s for obesity (Wegovy, Zepbound, or Saxenda).

While all state Medicaid programs include GLP-1s prescribed for Type 2 diabetes, only 36 states cover at least one of the FDA-approved GLP-1s for obesity (Wegovy, Zepbound, or Saxenda).

While all state Medicaid programs include GLP-1s prescribed for Type 2 diabetes, only 36 states cover at least one of the FDA-approved GLP-1s for obesity (Wegovy, Zepbound, or Saxenda).